Match Document Document Title
US20100168006 IN-PLANT PRODUCTION OF DIMERIC AND/OR OLIGOMERIC (COMPRISING THREE OR MORE UNITS) FORMS OF HUMAN APO A-1 PROTEIN MUTEINS  
The present invention encompasses a method for the production of Apolipoproteins in dimeric and/or oligomeric forms (comprising three or more units) of muteins of the human ApoA-1 protein in plant...
US20120021971 Functional Food Product Comprising Heat Shock Protein or a Hydrolysate Thereof  
The invention relates to a heat shock protein from alfalfa and/or a hydrolysate of a heat shock protein from alfalfa in the manufacture of a food product for the prophylactic or therapeutic...
US20130216479 SITE-SPECIFIC CHEMICAL MODIFICATION OF PROTEINS AT THEIR N-TERMINI, ENABLING THE FORMATION OF HOMOGENEOUS ADDUCTS  
Site-specific modifications of proteins at their N-termini are provided. In particular, a chemical modification of proteins at their N-termini via a transamination reaction to form homogeneous...
US20140120091 FUSION PROTEINS FOR THERAPY OF AUTOIMMUNE AND CARDIOVASCULAR DISEASE  
The present invention provides improved fusion proteins for therapy of autoimmune and cardiovascular disease.
US20110152171 HISTAMINE BINDING PROTEIN  
The invention relates to histamine binding proteins. The invention also relates to the use of such histamine binding proteins in the treatment and prevention of diseases.
US20120082668 SOLUBLE IL-17RA/RC FUSION PROTEINS AND RELATED METHODS  
Disclosed are antagonists of IL-17A and IL-17F. The antagonists are based on soluble IL-17RA and IL-17RC fusion proteins, including hybrid soluble receptors comprising portions of both IL-17RC and...
US20120295835 SGEF CONTROLS MACULAR, CORPUS CALLOSUM AND HIPPOCAMPAL FUNCTION AND DEVELOPMENT, LIVER HOMEOSTASIS, FUNCTIONS OF THE IMMUNE SYSTEM, FEVER RESPONSE ATHEROSCLEROSIS AND TUMOROGENIC CELL GROWTH  
The invention provides a composition comprising SGEF protein or gene as a therapeutic means to clinical or subclinical defects associated with anomalies of at least one from among the macula,...
US20120093776 METHODS FOR TREATING DISEASES USING A BONE MORPHOGENETIC PROTEIN  
Described herein are methods, uses, and pharmaceutical compositions for treating heart disease that include a bone morphogenetic protein (BMP). In addition, described herein are methods, uses, and...
US20130035282 METABOLIC AND CARDIOPROTECTION BY THE MYOKINE FOLLISTATIN-LIKE 1 POLYPEPTIDE  
Described herein are methods and compositions related to the discovery that the Follistatin-like 1 protein (Fstl-1) has metabolic and cardioprotective effects in vivo. Fstl-1 and portions and...
US20140155316 FIBROBLAST GROWTH FACTOR 1 PROTEIN FRAGMENTS AND METHODS OF USE  
The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and...
US20120165245 ANGIOGENICALLY EFFECTIVE UNIT DOSE OF FGF AND METHOD OF ADMINISTERING  
The present invention provides a unit dose comprising 0.2 μg/kg to 36 μg/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. Also provided is a pharmaceutical...
US20110236508 L-ARGININE-BASED FORMULATION FOR ORAL ABSORPTION  
A formulation comprising large quantities of l-arginine and/or fat plaque dissolving agents which is palatable, stench free, and does not evoke nausea. The formulation is adapted to facilitate the...
US20140147414 COMPOSITIONS AND METHODS FOR TREATMENT OF INTRACELLULAR DAMAGE  
Pre-implantation factor (PIF) may be used to treat intracellular damage. Aspects of the invention are directed to a method of treating intracellular damage comprising administering PIF to a...
US20100329985 TREATMENT AND PREVENTION OF INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES  
The present invention relates to the use of fragments of heat shock proteins for the treatment and/or prevention of autoimmune diseases such as arthritis or inflammatory diseases such as...
US20130190226 RECONSTITUTED HIGH DENSITY LIPOPROTEIN FORMULATION AND PRODUCTION METHOD THEREOF  
A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAI or fragment thereof, a lipid and a detergent at a level which is about...
US20110293725 CHIMERIC THERAPEUTICS, COMPOSITIONS, AND METHODS FOR USING SAME  
Chimeric therapeutics are disclosed that include a modified viral core protein and a nucleic acid bound to the modified viral core protein. The nucleic acid may be substantially homologous to a...
US20140057832 USE OF RELAXIN TO INCREASE ARTERIAL COMPLIANCE  
The present invention provides methods for increasing arterial compliance. The methods generally involve administering to an individual in need thereof an effective amount of relaxin. The present...
US20110111054 BMP-7 FOR USE IN TREATING VASCULAR SCLEROSIS  
The present invention relates to prevention and treatment of vascular sclerosis, vascular calcification (VC) and neointimal hyperplasia using a morphogen.
US20120077734 Methods and assays for treating conditions in which macrophages play a pathogenic role  
Methods and assays are disclosed for treating a subject with a disease or condition in which macrophages play a pathogenic role using agents that inhibit or down regulate Wiskott-Aldrich syndrome...
US20100331238 Human G protein-coupled receptor and modulators thereof for the treatment of atherosclerosis and atherosclerotic disease and for the treatment of conditions related to MCP-1 expression  
The present invention relates to methods of using a G protein-coupled receptor (GPCR) to identify whether a candidate compound is a modulator of atherogenesis. In certain embodiments, the GPCR...
US20110201542 Myeloid Protein Activation of Anti-Inflammatory and Anti-Hypoxic Pathway  
Provided are methods to enhance healing of wounds and tissue, especially during or pursuant to psychological and/or physical stress and to protect tissue from deleterious effects associated with...
US20140323389 METHODS FOR PREVENTING OR TREATING DISORDERS BY INCREASING BIOAVAILABILITY OF IRON AND RELATED PHARMACEUTICAL FORMULATION  
The present disclosure relates to methods of treating, ameliorating or preventing a disorder comprising administering a therapeutically effective amount of a composition to a subject in need...
US20110021413 METHODS OF SUPPRESSING MICROGLIAL ACTIVATION  
Methods of suppressing the activation of microglial cells in the Central Nervous System (CNS), methods of ameliorating or treating the neurological effects of cerebral ischemia or cerebral...
US20110274708 SHORT-FORM HUMAN MD-2 AS A NEGATIVE REGULATOR OF TOLL-LIKE RECEPTOR 4 SIGNALING  
The present invention is based on a novel, alternatively spliced human isoform of MD-2 (MD-2s). In addition, the present invention relates to modified MD-2 proteins, wherein one or more tyrosine...
US20110262386 METHODS OF TREATING INFLAMMATION  
Disclosed herein, in certain embodiments, is a method for treating an MIF-mediated disorder. In some embodiments, the method comprises administering an active agent that inhibits (i) MIF binding...
US20130046283 METHODS AND INTRAVASCULAR TREATMENT DEVICES FOR TREATMENT OF ATHEROSCLEROSIS  
Methods and intravascular treatment devices for treating atherosclerosis are provided.
US20120315303 METHODS AND INTRAVASCULAR TREATMENT DEVICES USING PACLITAXEL FOR TREATMENT OF ATHEROSCLEROSIS  
Methods and intravascular treatment devices for treating atherosclerosis are provided.
US20130171211 METHODS AND USES FOR INHIBITING PLATELET COAGULATION  
The present disclosure provides methods and uses of Slit proteins and nucleic acids for inhibiting platelet coagulation and related disorders. Further provided is a vascular device coated with...
US20110305732 METHODS AND USES FOR INHIBITING PLATELET COAGULATION  
The present disclosure provides methods and uses of Slit proteins and nucleic acids for inhibiting platelet coagulation and related disorders. Further provided is a vascular device coated with...
US20110059885 TREATMENT OF DISEASES AND CONDITIONS MEDIATED BY EICOSANOIDS  
The method of the invention relates to an OmCI polypeptide or a polynucleotide encoding an OmCI polypeptide for the treatment of a disease or condition mediated by a leukotriene or hydroxyeicosanoid.
US20120046218 GLYCOSAMINOGLYCAN-ANTAGONISING MCP-I MUTANTS AND METHODS OF USING SAME  
Novel mutants of human monocyte chemoattractant protein 1 (MCP-1) with increased glycosaminoglycan (GAG) binding affinity and knocked-out or reduced GPCR activity compared to wild type MCP-1, and...
US20130190224 TREATMENT OF FIBROSIS-RELATED DISORDERS USING FIBRONECTIN BINDING PROTEINS AND POLYPEPTIDES  
The present invention is directed to various uses of fibronectin binding proteins or polypeptides for treating and preventing fibrosis and fibrosis related conditions. The fibronectin binding...
US20110243923 ORGANIC COMPOUNDS  
The present invention relates to modulators of the interaction between Epstein-Barr Virus induced receptor-2 (EBi2) and cholest-5-ene-3b,7b,25-triol (7, 25-dihydroxycholesterol) (“7,25DHC”) and/or...
US20150010552 COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION AND FIBROSIS  
The present invention features compositions featuring agents that bind to denatured collagen and methods of using such agents to treat or prevent fibrosis or inflammation in a subject.
US20120237504 COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION AND FIBROSIS  
The present invention features compositions featuring agents that bind to denatured collagen and methods of using such agents to treat or prevent fibrosis or inflammation in a subject.
US20140135258 Treatment of Inflammatory Bowel Diseases with Mammal Beta Defensins  
The present invention relates to treatment of inflammatory bowel diseases with mammal beta defensins.
US20130164306 COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE AND INFLAMMATORY DISORDERS  
Ligand-specific HVEM variants, compositions comprising such variants, and methods of treating inflammatory diseases comprising administering such variants, are provided.
US20150132321 METHODS OF MODULATING ANGIOGENESIS VIA TRPV4  
The present invention relates to methods of inhibiting capillary endothelial (CE) cell migration, the formation of CE networks and angiogenesis, and uses thereof for the purpose of treating...
US20130310304 COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATHEROSCLEROSIS  
Novel HDL mimetic polypeptides are disclosed, particularly Apo A-1 Carnivora/Sapien polypeptides. Nucleic acids coding for the Apo A-1 Carnivora/Sapien polypeptides are also disclosed, as are...
US20130210703 FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS THAT BIND PCSK9  
The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat...
US20130071392 Small Heat Shock Proteins and Active Fragments Thereof as a Therapy for Inflammation and Ischemia  
The invention provides methods for treating inflammatory diseases by administering to the subject an effective amount of an agent that provides small heat shock protein activity, where the dose is...
US20140342976 COMPOSITIONS AND METHODS FOR MINIMALLY-INVASIVE SYSTEMIC DELIVERY OF PROTEINS INCLUDING TGF-BETA SUPERFAMILY MEMBERS  
The present invention is directed to methods and compositions for systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-β superfamily. According...
US20140187473 Compositions and Methods for Minimally-Invasive Systemic Delivery of Proteins Including TGF-Beta Superfamily Members  
The present invention is directed to methods and compositions for systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-β superfamily. According...
US20110118173 METHOD OF DELIPIDATION OF HDL USING SERUM OPACITY FACTOR TO PREVENT, INHIBIT, AND/OR REVERSE ATHEROSCLEROSIS  
This invention relates to delivering a therapeutically active serum opacity factor or an anti-atherosclerotic therapeutic lipoprotein generated from interaction with serum opacity factor to an...
US20110009312 Albumin Fusion Proteins  
The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors...
US20120171194 Method of Cell Differentiation and Uses Therefor in Screening, Diagnosis and Therapy  
The present invention provides a method of producing non-haematopoietic cells, in particular cells having one or more properties of endothelial cells, from monocytes. A range of diagnostic and...
US20120276126 LACTOFERRIN IN THE TREATMENT OF MALIGNANT NEOPLASMS AND OTHER HYPERPROLIFERATIVE DISEASES  
The present invention relates to methods of treating a hyperproliferative disease by administering a composition of lactoferrin alone or in combination with standard anti-cancer therapies.
US20110076295 LACTOFERRIN IN THE TREATMENT OF MALIGNANT NEOPLASMS AND OTHER HYPERPROLIFERATIVE DISEASES  
The present invention relates to methods of treating a hyperproliferative disease by administering a composition of lactoferrin alone or in combination with standard anti-cancer therapies.
US20120311728 METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ATHEROSCLEROSIS  
The present invention relates to the prevention or treatment of atherosclerosis, in particular to a group X sPLA2 polypeptide for use in the treatment of atherosclerosis.
US20140286906 USE OF IGF-1 IN THE MODULATION OF TREG CELL ACTIVITY AND THE TREATMENT AND PREVENTION OF AUTOIMMUNE DISORDERS OR DISEASES  
The present invention relates to the use of the Insulin-like growth factor-I (IGF-1) in immune modulation and/or in the treatment or prevention of pathogenic or aberrant immune responses or...